Prescription Medicines
Duvalcan Tab. 0.2mg
- Product Category
- hair solvent
- Active Ingredients
- Dutasteride
- Appearance
- Yellow oblong film-coated tablet
01 / 02
1. Composition and Strength : 1 tablet
- Active ingredient: Dutasteride (in-house specification) ······ 0.2mg
- Additives: Calcium silicate, microcrystalline cellulose (101), microcrystalline cellulose (102), butylhydroxytoluene, magnesium stearate, opadry yellow (03B62323), colloidal silicon oxide, crospovidone, polyoxyl 35, castor oil, propylene glycol monocaprylate, hydroxypropyl cellulose, D-mannitol
2. Effectiveness
Treatment of androgenetic alopecia in adult men (18-50 years old)
3. Dosage and dosage
The recommended dosage of this drug is 1 tablet (0.2 mg) once a day.
This medication should be swallowed whole without chewing or breaking, as it may cause irritation of the oropharyngeal mucosa. This medicine can be taken without regard to meals.
There is no need to adjust the dose of this drug in patients with renal impairment. Because there are no data on the administration of this drug to patients with hepatic impairment, the recommended dosage of this drug in patients with hepatic impairment has not been established.
4. Precautions for use
1. Warning
1) Risk to male fetus when exposed to women
This drug is absorbed through the skin. Therefore, this drug should not be handled by women who are pregnant or may become pregnant due to the potential for absorption of this drug and the potential risk of fetal abnormalities to the male fetus. Additionally, women should be careful whenever handling this medicine and should not touch broken or broken pieces of this medicine.
2) Pediatric
Because this medication is absorbed through the skin, children should not touch broken or broken pieces of this medication.
2. Do not administer to the following patients.
1) Women
2) Children under 18 years of age
3) Patients with hypersensitivity to this drug, other components of this drug, or other 5α-reductase inhibitors
3. Administer with caution to the following patients.
1) Adult male planning to become pregnant (when using this drug to treat male pattern hair loss, it may affect reproductive function, so administer with caution under the doctor's judgment)
2) Patients with large urinary retention or severe reduction in urinary flow
In these patients, administration of 5α-reductase inhibitors may not be advisable, and urinary retention should be carefully monitored.
3) Patients with liver impairment
The effect of hepatic impairment on the pharmacokinetics of this drug has not been studied. Since this drug is extensively metabolized and has a half-life of about 3 to 5 weeks, this drug should be administered with caution to patients with liver function abnormalities.
4) Concurrent administration with a strong CYP3A4 inhibitor
Although this drug is extensively metabolized, no studies have been conducted on drug interactions related to metabolism and the effects of strong CYP3A4 inhibitors have not been tested. Due to the potential for drug interactions, caution should be exercised when administering this drug to patients chronically taking strong CYP3A4 enzyme inhibitors (e.g. ritonavir).
4. Adverse reactions
1) Adverse reactions observed in clinical trials
① Adverse reactions that occurred when this drug (dutasteride 0.2 mg) was administered alone in clinical trials for male pattern hair loss
The safety of this drug (dutasteride 0.2mg) group, placebo group, and exploratory dutasteride 0.5mg group were evaluated and compared in 139 male androgenetic alopecia patients after 24 weeks compared to the baseline.
Of the total 139 test subjects, 50 adverse reactions were reported in 29 (20.86%) and 24 adverse drug reactions (ADRs) were reported in 16 (11.51%). Three serious adverse events (SAEs) were reported in 3 patients (2.16%) and were not related to this drug.
The adverse reactions judged to be related to this drug (dutasteride 0.2mg) were as follows.
[Table 1] Adverse drug reactions (* refer to manual)
② Adverse reactions that occurred when dutasteride 0.5mg was administered alone in clinical trials for male pattern hair loss
Dutasteride 0.5 mg was studied for the treatment of male pattern hair loss in two 6-month placebo-controlled phase 3 clinical trials and one phase 2 clinical trial. In these clinical trials, the adverse reactions that investigators judged to be related to dutasteride 0.5 mg (frequency greater than 2%) are as follows and were reported more frequently with dutasteride 0.5 mg compared to placebo.
[Table 2] Adverse reactions judged to be related to dutasteride 0.5mg (frequency of 2% or more) (* refer to manual)
2) Domestic post-marketing survey
The information specified below is based on what was collected during post-marketing surveillance for Dutasteride 0.5 mg.
① Results of a post-marketing use survey conducted on 712 adult males (18 to 41 years old) who received 0.5 mg of dutasteride for the treatment of male pattern hair loss over a period of 4 years (July 23, 2009 - July 22, 2013) for re-examination in Korea.
- The adverse event rate was reported to be 15.4% (110/712 people, 138 cases) regardless of causal relationship. Among these, the incidence of adverse drug reactions for which a causal relationship with 0.5 mg of dutasteride cannot be ruled out was 9.3% (66/712 people, 80 cases), with 9 cases of decreased libido, 8 cases of indigestion, 7 cases of erectile dysfunction, 5 cases each of fatigue and increased SGPT, and 4 cases each of rash and sexual dysfunction. The occurrence rate of serious adverse events was 0.6% (4/712 people, 5 cases) regardless of causal relationship. Two cases of pharyngitis, one case each of appendicitis, fracture, and viral infection were reported, but they did not correspond to serious adverse drug reactions. The incidence of unexpected adverse events was 8.1% (58/712 people, 69 cases) regardless of causal relationship: 6 cases of pharyngitis, 5 cases of increased SGPT, 4 cases each of acne and fungal dermatitis, 3 cases each of seborrhea, skin disease, and increased SGOT, 2 cases each of folliculitis, eczema, appendicitis, fatty liver, chest pain, palpitations, warts, contact dermatitis, Dry skin, peptic ulcer, gastritis, gastroenteritis, drowsiness, bilirubinemia, upper respiratory tract infection, fracture, unspecified abrasion, surgical intervention, laceration, hyperuricemia, hypertriglyceridemia, weight gain, paresthesia, decreased testosterone, skeletal pain, plantar fasciitis, viral infection, bacterial infection, purpura, epistaxis, blepharitis, benign laryngeal neoplasm, nephrolithiasis, dysgeusia, telangiectasia. It was reported in order of 1 case, of which the adverse drug reaction rate for which a causal relationship with 0.5 mg of dutasteride cannot be ruled out was 3.5% (25/712 people, 29 cases), with 5 cases of increased SGPT, 3 cases of increased SGOT, 2 cases each of acne, skin disease, folliculitis, palpitations, fungal dermatitis, seborrhea, warts, drowsiness, bilirubinemia, pharyngitis, surgical intervention, One case each of hypertriglyceridemia, weight gain, paresthesia, decreased testosterone, nosebleeds, and dysgeusia were reported in that order.
② As a result of integrated evaluation of the domestic reexamination adverse event and spontaneous side effect reporting data for Dutasteride 0.5mg with the adverse event reporting data reported for all domestically approved drugs at the end of reexamination, the newly confirmed adverse events that were statistically significantly more reported in Dutasteride 0.5mg compared to the adverse events reported in all other drugs are as follows. However, this result does not mean that a causal relationship has been proven between the ingredient and the following adverse events.
- Skin and appendage disorders: acne, dry skin
- Visual impairment: visual abnormality
- Liver and biliary tract diseases: fatty liver
- Metabolic and nutritional diseases: thirst
- Urinary system diseases: urinary abnormalities, hematuria
- Reproductive dysfunction (male): Semen abnormality
- Neoplasm: Gastric carcinoma
5. General precautions
1) Blood donation
To prevent the drug from being administered to a pregnant woman during a blood transfusion, patients taking this drug should not donate blood until at least 6 months have passed since the last time they took this drug.
2) Prostate-specific antigen (PSA)
① This drug reduces total serum PSA concentration. Therefore, in order to interpret the serum PSA value in men taking this drug, the initial value of PSA concentration must be reset 3 to 6 months after administration of this drug, and this new initial value should be used to evaluate potential changes in PSA value related to cancer.
② For patients taking this drug who need prostate cancer screening, a new PSA baseline value must be established 6 months after taking this drug. It is recommended to monitor PSA values regularly thereafter. A confirmed increase in PSA from the nadir level during treatment with this drug may be a sign of the presence of prostate cancer or refractoriness to treatment with this drug and should be carefully evaluated, even if such values are within the normal range for men not taking 5α-reductase inhibitors. In interpreting PSA values for patients taking this drug, previous PSA values should be referenced for comparison. Administration of this drug does not preclude the use of PSA as an adjunct to the diagnosis of prostate cancer after a new PSA baseline level has been established.
③ The total serum concentration of PSA will return to the initial value within 6 months after discontinuation of this drug.
④ The ratio of free PSA value to total PSA value remains constant while taking this drug. If a physician chooses the percentage of free PSA to diagnose prostate cancer in male patients taking this drug, no correction to this value is necessary.
3) Prostate cancer
In a clinical trial in which 0.5 mg of dutasteride or placebo was administered for 4 years to 8,231 men aged 50 to 75 years with a baseline PSA level of 2.5 ng/mL to 10.0 ng/mL and a previous negative biopsy for prostate cancer, 1,517 men were diagnosed with prostate cancer. The frequency of Gleason grade 8 to 10 prostate cancer was higher in the dutasteride 0.5 mg group (n=29, 1.0%) compared to the placebo group (n=19, 0.5%). There was no increase in the incidence of Gleason grade 5 to 6 or 7 to 10 prostate cancer. The causal relationship between dutasteride and high-grade prostate cancer has not been proven, and the clinical significance of the numerical imbalance is unknown. However, because dutasteride may increase the risk of developing high-grade prostate cancer, men taking this drug should be periodically evaluated for their risk of prostate cancer, including a PSA test. In a 2-year extended follow-up study of the clinical trial subjects, similar results were observed regarding the development of new prostate cancer (dutasteride 0.5mg [n=14, 1.2%], placebo [n=7, 0.7%]), among which there were no newly confirmed cases of Gleason grade 8 to 10 prostate cancer.
4) Breast cancer was reported in men who received 0.5 mg of dutasteride during clinical trials and post-marketing surveillance. In epidemiological studies, no increase in the risk of developing male breast cancer was observed following administration of 5α-reductase inhibitors. Physicians should instruct patients to promptly report any changes in breast tissue, such as lumps or nipple discharge. The causal relationship between long-term administration of dutasteride and the development of male breast cancer is not clear.
5) Effects on fertility
When dutasteride 0.5mg/day was administered to healthy subjects aged 18 to 52 years (dutasteride n=27, placebo n=23) for 52 weeks, the effect of dutasteride 0.5mg on semen characteristics was evaluated during the 52-week administration period and 24 weeks of follow-up period after the end of administration. At week 52, the average rate of decrease from initial values in total sperm count, semen volume, and sperm motility in the dutasteride 0.5 mg group was 23%, 26%, and 18%, respectively, when adjusted for the average decrease rate in the placebo group. Sperm concentration and sperm morphology were not affected. After a 24-week follow-up period, the average rate of change in total sperm count in the dutasteride 0.5 mg group was 23% lower than the initial value. At each test point, the average values of all semen-related evaluation variables were within the normal range, and there were no clinically significant changes (preliminarily defined as 30%). However, in two subjects in the dutasteride 0.5 mg treatment group, the sperm count at week 52 decreased by more than 90% from the initial value, and partially recovered at week 24 after the end of administration. The clinical significance of the effect of dutasteride on the characteristics of semen, which is the reproductive capacity of each patient, has not yet been revealed.
6) Information for patients
① Pregnant women or women with the potential to become pregnant should not handle this drug due to its absorption potential and potential risk to the developing male fetus due to absorption.
② Patients should be informed that the amount of ejaculation may decrease in some patients while taking this drug. Reduced ejaculate volume does not appear to interfere with normal sexual function. In clinical trials, erectile dysfunction and decreased sexual desire occurred in a small number of subjects administered this drug (dutasteride 0.2 mg), dutasteride 0.5 mg, or placebo, and the researchers judged it to be related to the test drug.
③ To prevent this drug from being administered to pregnant women during blood transfusion, patients taking this drug should not donate blood until at least 6 months have passed since the last time they took this drug.
7) Based on the pharmacodynamic and pharmacokinetic properties of this drug, this drug is not expected to affect the ability to drive or operate machinery.
8) Heart failure
In two 4-year clinical trials, the frequency of heart failure (adverse reactions mainly reported as heart failure and congestive heart failure) was found to be higher in patients receiving dutasteride 0.5 mg in combination with an α-blocker (mainly tamsulosin) than in patients not receiving the combination. The incidence of heart failure in these two trials was low (≤1%) and differed between the two trials. No imbalance in the overall frequency of cardiovascular adverse events was observed in either trial. A causal relationship between dutasteride (either alone or in combination with α-blockers) and heart failure has not been established.
6. Interaction
1) In in vitro drug metabolism studies, dutasteride was metabolized by human CYP3A4, so the blood concentration of this drug may increase in patients taking CYP3A4 inhibitors. Therefore, caution should be exercised when administering this drug to patients chronically taking strong CYP3A4 inhibitors.
2) When administered at 0.5 mg of dutasteride, it did not inhibit the in vitro metabolism of substrates of major human CYP450 isoenzymes (CYP1A2, CYP2A6, CYP2E1, CYP2C8, CYP2C9, CYP2C19, CYP2B6, and CYP2D6) at a concentration of 1000 ng/mL, which is 25 times higher than the human steady-state serum concentration. Additionally, dutasteride did not induce CYP P450 isoenzymes CYP1A, CYP2B, or CYP3A in in vivo tests in dogs and rats.
3) Calcium channel antagonist: Dutasteride 0.5mg As a result of pharmacodynamic (PK) analysis of phase 2 clinical trial data, a decrease in clearance of dutasteride was confirmed when the CYP3A4 inhibitor verapamil (-37%, n = 6) and diltiazem (-44%, n = 5) were co-administered. Conversely, when dutasteride 0.5 mg was co-administered with amlodipine (+7%, n = 4), a calcium channel antagonist rather than a CYP3A4 inhibitor, no decrease in the clearance of dutasteride was observed.
When co-administered with CYP3A4 inhibitors (e.g. verapamil and diltiazem), the decreased clearance of dutasteride and the resulting increased exposure are not considered clinically significant due to the wide safety margin of dutasteride (up to 10 times the dose of 0.5 mg of dutasteride has been administered to patients for up to 6 months), so dose adjustment is not recommended.
4) α-Adrenergic blockers: In a cross-over study on healthy volunteers, when 0.5 mg of dutasteride was co-administered with tamsulosin or terazosin for 2 weeks, it did not affect the steady-state pharmacokinetics or pharmacodynamics of these α-adrenergic blockers. The rate of change in 5α-dihydrotestosterone (DHT) concentration during combined administration was similar to that when dutasteride 0.5 mg was administered alone.
In clinical trials, 0.5 mg of dutasteride and tamsulosin were administered in combination for 24 weeks, and then 0.5 mg of dutasteride and tamsulosin were administered together for 12 weeks, or 0.5 mg of dutasteride was administered alone. After a 12-week administration period, compared to the dutasteride 0.5mg single administration group, there were no excessively severe adverse reactions in the combination administration group or discontinuation of the test drug due to adverse reactions.
5) In in vitro tests, dutasteride replaces warfarin, diazepam, acenocoumarol, phenprocoumon, or phenytoin at the plasma protein binding site, or these model compounds do not replace dutasteride.
6) Warfarin: When dutasteride 0.5 mg/day was co-administered with warfarin to 23 healthy subjects for 3 weeks, it did not change the steady-state pharmacokinetics of S- or R-warfarin isomers, nor did it change the effect of warfarin on prothrombin time.
7) Digoxin: When dutasteride 0.5 mg/day was co-administered with digoxin to 20 healthy subjects for 3 weeks, it did not change the steady-state pharmacokinetics of digoxin.
8) Cholestyramine: When 12 g of cholestyramine was administered to 12 normal volunteers one hour after a single dose of 5 mg of dutasteride, it did not affect the relative bioavailability of dutasteride.
9) Other combination therapy: Although interaction tests with other drugs were not specifically conducted, approximately 90% of subjects who received 0.5 mg of dutasteride in phase 3 clinical trials were taking other drugs concurrently. In clinical trials, when 0.5 mg of dutasteride was co-administered with antihyperlipidemic agents, angiotensin-converting enzyme (ACE) inhibitors, β-adrenergic blockers, calcium channel blockers, corticosteroids, diuretics, non-steroidal anti-inflammatory drugs (NSAIDs), phospho-diesterase Type V (PDE5) inhibitors, and quinolone antibiotics, co-administration with dutasteride was effective. There were no clinically significant negative interactions attributable to this study.
7. Administration to pregnant and lactating women
1) Administration to pregnant women
This drug is contraindicated in women. This drug was not tested in women because nonclinical study results suggested that external genital development may be impaired in male fetuses conceived by exposed women due to inhibition of circulating dihydrotestosterone (DHT) levels.
2) Administration to nursing mothers
This drug is contraindicated in women. It is not known whether this drug passes into human breast milk.
8. Administration to children
This drug is contraindicated in children under 18 years of age. Safety and efficacy in children under 18 years of age have not been established.
9. Administration to elderly people
Clinical trials for the treatment of male pattern hair loss were conducted on adult male patients under the age of 50. There are no efficacy data for patients with male pattern hair loss over 50 years of age.
10. Effect on clinical test values
1) PSA level
As a result of observing PSA values at 12 and 24 weeks in subjects who received this drug (dutasteride 0.2 mg) during clinical trials, there was a statistically significant decrease compared to the baseline.
During clinical trials, the PSA value decreased by 20% within one month of administration in approximately half of the subjects who received 0.5 mg of dutasteride. Six months after administration, the PSA value stabilized to a new initial value of approximately 50% of the value before administration. Even after administering 0.5 mg of dutasteride for up to 2 years, the PSA value continued to decrease by up to 50%.
The initial PSA value must be reset 3 to 6 months after administering this drug.
2) Hormone levels
Testosterone and dihydrotestosterone levels were observed at 12 and 24 weeks in subjects who received this drug (dutasteride 0.2 mg) during the clinical trial. As a result, testosterone increased statistically significantly and dihydrotestosterone decreased compared to the baseline.
In healthy adults, no clinically significant changes were observed in the levels of globulin-binding sex hormones, estradiol, luteinizing hormone, follicle-stimulating hormone, thyroxine (free T4), and dehydroepiandrosterone when dutasteride 0.5 mg (n = 26) was administered for 52 weeks compared to placebo (n = 23). Total testosterone (97.1ng/dL, p<0.003) at 8 weeks and thyroid-stimulating hormone (TSH) (0.4mcIU/mL, p<0.05) at 52 weeks were statistically significantly increased compared to the placebo group. Within the dutasteride 0.5 mg administration group, the median change from baseline was 17.9% at 8 weeks for testosterone and 12.4% at 52 weeks for TSH. During the 24-week follow-up period after discontinuation of dutasteride, the average values of testosterone and TSH in subjects with analyzable samples recovered to baseline levels.
11. Treatment in case of overdose
There is no specific antidote for this drug, so when symptoms of overdose are suspected, appropriate supportive therapy should be administered considering the long half-life of this drug.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Removing medicines from their original container and storing them in another container may cause accidents due to misuse of medicines or cause a decrease in the quality of medicines, so keep them in their original containers.
13. Information for experts
1) Pharmacological action
Dutasteride is a 5α-reductase inhibitor that inhibits the conversion of testosterone to dihydrotestosterone (DHT).
2) Pharmacokinetic information
One randomized, open-label, single-dose, cross-over design, phase 1 clinical trial was conducted to compare and evaluate the pharmacokinetics and safety of this drug (dutasteride 0.2 mg) and Avodart soft capsule 0.5 mg (dutasteride 0.5 mg).
As a result of measuring dutasteride in the blood of 23 healthy adult men, the point estimate (90% CI) of the geometric mean ratio of log-transformed AUCt/dose and Cmax/dose between administration groups (0.5 mg of this drug/Avodart soft capsule) was 0.3150 (0.2740-0.3621), respectively. It was observed as 0.7441 (0.6527-0.8483).
3) Clinical trial information
One multicenter, randomized, double-blind, placebo-controlled, parallel phase 3 clinical trial was conducted to compare and evaluate the safety and efficacy of this drug (dutasteride 0.2mg, test group), placebo (placebo group), and dutasteride 0.5mg (exploration group) in 137 male patients with androgenetic alopecia once daily for 24 weeks.
The subjects of the clinical trial were men aged 18 or older and 50 or younger who were diagnosed with androgenetic alopecia corresponding to M2 or C2 or higher, V1 or F1 or higher (excluding M2 or M3 alone) according to the BASP classification. The most frequent age group was 40-50 years old (approximately 60% of the total), and among the BASP classifications, M2-3/V1-3 was included at approximately 60%, M2-3/F1-3 at approximately 25%, and other classifications accounted for less than 10% each.
As a primary efficacy endpoint, the change in the total number of hairs in a unit area circle (㎠) at 24 weeks compared to the baseline was evaluated, and a statistically significant increase was observed in the test group compared to the placebo group, showing superiority over placebo (p value = 0.0072).
[Table 3] Change in total number of hairs in unit area circle (㎠) at 24 weeks compared to baseline (* refer to manual)
4) Toxicity test information
(1) Central nervous system toxicity
When dutasteride was repeatedly administered orally to rats and dogs, non-specific, reversible, and central nervous system-mediated toxicity was observed in some experimental animals. However, no relevant histopathological changes were observed when dutasteride was administered at 425 and 315 times the expected clinical exposure, respectively, at 0.5 mg per day.
(2) Carcinogenicity
In a 2-year carcinogenicity study in B6C3F1 mice, males were administered doses of 3, 35, 250, and 500 mg/kg/day, and females were administered doses of 3, 35, and 250 mg/kg/day. An increase in the incidence of benign hepatocellular adenoma was confirmed only in females administered 250 mg/kg/day (290 times the expected clinical exposure when administering 0.5 mg of dutasteride per day). Two of the three major metabolites in humans were identified in mice. It is not known whether exposure to these metabolites in mice is lower than in humans.
In a 2-year carcinogenicity study on Han Wistar rats, doses of 1.5, 7.5, and 53 mg/kg/day were administered to males, and doses of 0.8, 6.3, and 15 mg/kg/day to females. Leydig cell adenomas increased in the testes of males administered 53 mg/kg/day (135 times the expected clinical exposure when administered 0.5 mg of dutasteride per day), and Leydig cells increased in the testes of males administered 7.5 mg/kg/day (52 times the expected clinical exposure when administered 0.5 mg of dutasteride per day) and 53 mg/kg/day. An increased incidence of hyperplasia was observed. A positive correlation between the proliferation changes of Leydig cells and the increase in circulating luteinizing hormone levels was demonstrated by 5α-reductase administration, which was consistent with the effect on the hypothalamic-pituitary-testicular axis after 5α-reductase inhibition. At the carcinogenic dose in rats, rat luteinizing hormone levels increased by 167%. In this study, the carcinogenicity of dutasteride's major metabolites in humans was tested when exposed to approximately 1 to 3 times the expected clinical exposure when administered at 0.5 mg per day. In carcinogenicity tests on rats, benign stromal cell tumors increased when administered at high doses (158 times the expected clinical exposure when dutasteride was administered at 0.5 mg per day). However, the endocrine mechanisms thought to be involved in mesangial cell hypertrophy and adenomas in rats are not relevant to humans. Carcinogenicity studies in mice showed no clinically relevant effects on tumor profile.
(3) Hereditary
Dutasteride did not show genotoxicity in various in vitro and in vivo tests.
The results of the bacterial mutagenicity test (Ames test), chromosomal aberration test in CHO cells, and micronucleus test in rats did not indicate the possibility of dutasteride being genotoxic. The two major metabolites in humans were also not mutagenic in the Ames test or modified Ames test.
(4) Reproductive and developmental toxicity
When dutasteride 0.05, 10, 50, and 500 mg/kg/day (0.1 to 110 times the expected clinical exposure when administering 0.5 mg of dutasteride per day) was administered to sexually mature male rats for up to 31 weeks, reproductive performance decreased in a dose- and time-dependent manner, and the number of sperm in the epididymis decreased, but sperm concentration did not decrease (50, 500mg/kg/day), the weight of the epididymis, prostate, and seminal vesicles decreased, and microscopic changes appeared in the male reproductive organs. In all test drug administration groups, reproductive function recovered at 6 weeks of recovery, and sperm count became normal at the end of 14 weeks of recovery. 5α-reductase-related changes included cytoplasmic vacuolization of epididymal tubular epithelial cells and decreased cytoplasmic content of epithelial cells, consistent with decreased secretory activity in the prostate and seminal vesicles. In the low-dose group, microscopic changes no longer appeared at 14 weeks of recovery, and there was partial recovery in the remaining dose groups. When males administered 10, 50, or 500 mg/kg/day for 29 to 30 weeks were mated with females not administered the test drug, low concentrations (0.6 to 17 ng/mL) of dutasteride were detected in the serum of the females. Dutasteride caused a reversible decrease in fertility in male rats, which is consistent with its pharmacological activity in 5α-reductase inhibition on accessory reproductive organs. This effect is not considered clinically significant because there was no effect on sperm development, concentration, or motility.
In an embryo-fetal development study in female rats, oral administration of dutasteride 0.05, 2.5, 12.5, and 30 mg/kg/day resulted in feminization of male fetuses (reduced anogenital distance) and male neonates (nipple development, hypospadias, and preputial gland swelling) at all doses. In relation to weight loss, an increased incidence of skeletal muscle deformation related to delayed ossification was observed at doses of 12.5 and 30 mg/kg/day (56 to 111 times the expected clinical exposure when administering 0.5 mg of dutasteride per day). In addition, at doses above 2.5 mg/kg/day (2 to 10 times the expected clinical exposure when administering 0.5 mg of dutasteride per day), the number of litters decreased, and embryo resorption and feminization of male fetuses increased. Fetal weight also decreased at doses above 0.05 mg/kg/day (less than 0.02 times the expected clinical exposure when administering 0.5 mg of dutasteride per day).
In a perinatal orally administered test to rats, dutasteride was administered at doses of 0.05, 2.5, 12.5, and 30 mg/kg/day. Feminization of the genitalia of F1 generation male neonates (e.g., decreased anogenital distance, increased hypospadias, and nipple development) was evident at doses above 2.5 mg/kg/day (14 to 90 times the estimated clinical exposure for dutasteride at 0.5 mg/day). At a dose of 0.05 mg/kg/day (0.05 times the expected clinical exposure when administering 0.5 mg of dutasteride per day), there was a small but statistically significant decrease in anogenital distance as evidence of feminization. When 2.5 to 30 mg/kg/day was administered, the gestation period in female mothers increased, the time to vaginal opening in female newborns, and the seminal vesicle weight in male newborns decreased. The effect on neonatal stimulation response was observed at doses higher than 12.5 mg/kg/day. At the dose of 30mg/kg/day, the number of stillbirths increased.
Feminization of male fetuses is an expected physiological result of inhibition of conversion of testosterone to DHT by administration of 5α-reductase inhibitors. These results are similar to those observed in male newborns genetically deficient in 5α-reductase.
In a rabbit embryo-fetal test, 30, 100, and 200 mg/kg (28 to 93 times the expected clinical exposure when dutasteride is administered at 0.5 mg per day) was administered on days 7 to 29 of conception, which corresponds to the final period of external genitalia development. When the papillary papillae of the fetuses were evaluated histologically, evidence for feminization of male fetuses was found at all doses. A second embryo-fetal study in rabbits administered doses of 0.05, 0.4, 3.0, and 30 mg/kg/day (0.3 to 53 times the estimated clinical exposure for dutasteride administered at 0.5 mg/day) also showed evidence of genital feminization in male fetuses at all doses. It is not known whether major human metabolites are present in rabbits or rhesus monkeys. However, when dutasteride was administered intravenously during the embryo-fetal development period of pregnant monkeys at doses up to 2010 ng/animal/day, no harmful maternal or fetal toxicity was observed. In an embryo-fetal development test (12/group) in rhesus monkeys, dutasteride 400, 780, 1325, and 2010 ng/day administered intravenously on days 20 to 100 of conception did not cause any adverse reactions in the development of male external genitalia. In monkeys administered the highest dose, a decrease in the weight of the fetal adrenal gland, a decrease in the weight of the fetal prostate, and an increase in the weight of the fetus's ovaries and testes were observed. The maximum concentration of dutasteride detected in the semen of a man who received repeated oral administration of 0.5 mg of dutasteride for 12 months was 14 ng/mL. Assuming that dutasteride is 100% absorbed by a 50 kg woman through 5 mL of semen per day, the maximum amount of dutasteride that can be exposed is 1.4 ng/kg. In an embryo-fetal development test administered intravenously to rhesus monkeys, there was no effect on male fetal development even at a concentration of 260ng/kg (corresponding to 186 times the maximum exposure to women through human semen when dutasteride is administered at 0.5mg per day) when converted to ng/kg. Because dutasteride has a very high binding rate (> 96%) to proteins in human semen, vaginal absorption is likely to be reduced.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/box (10 tablets/PTPX3)
7. Period of use
36 months from date of manufacture
- Active ingredient: Dutasteride (in-house specification) ······ 0.2mg
- Additives: Calcium silicate, microcrystalline cellulose (101), microcrystalline cellulose (102), butylhydroxytoluene, magnesium stearate, opadry yellow (03B62323), colloidal silicon oxide, crospovidone, polyoxyl 35, castor oil, propylene glycol monocaprylate, hydroxypropyl cellulose, D-mannitol
2. Effectiveness
Treatment of androgenetic alopecia in adult men (18-50 years old)
3. Dosage and dosage
The recommended dosage of this drug is 1 tablet (0.2 mg) once a day.
This medication should be swallowed whole without chewing or breaking, as it may cause irritation of the oropharyngeal mucosa. This medicine can be taken without regard to meals.
There is no need to adjust the dose of this drug in patients with renal impairment. Because there are no data on the administration of this drug to patients with hepatic impairment, the recommended dosage of this drug in patients with hepatic impairment has not been established.
4. Precautions for use
1. Warning
1) Risk to male fetus when exposed to women
This drug is absorbed through the skin. Therefore, this drug should not be handled by women who are pregnant or may become pregnant due to the potential for absorption of this drug and the potential risk of fetal abnormalities to the male fetus. Additionally, women should be careful whenever handling this medicine and should not touch broken or broken pieces of this medicine.
2) Pediatric
Because this medication is absorbed through the skin, children should not touch broken or broken pieces of this medication.
2. Do not administer to the following patients.
1) Women
2) Children under 18 years of age
3) Patients with hypersensitivity to this drug, other components of this drug, or other 5α-reductase inhibitors
3. Administer with caution to the following patients.
1) Adult male planning to become pregnant (when using this drug to treat male pattern hair loss, it may affect reproductive function, so administer with caution under the doctor's judgment)
2) Patients with large urinary retention or severe reduction in urinary flow
In these patients, administration of 5α-reductase inhibitors may not be advisable, and urinary retention should be carefully monitored.
3) Patients with liver impairment
The effect of hepatic impairment on the pharmacokinetics of this drug has not been studied. Since this drug is extensively metabolized and has a half-life of about 3 to 5 weeks, this drug should be administered with caution to patients with liver function abnormalities.
4) Concurrent administration with a strong CYP3A4 inhibitor
Although this drug is extensively metabolized, no studies have been conducted on drug interactions related to metabolism and the effects of strong CYP3A4 inhibitors have not been tested. Due to the potential for drug interactions, caution should be exercised when administering this drug to patients chronically taking strong CYP3A4 enzyme inhibitors (e.g. ritonavir).
4. Adverse reactions
1) Adverse reactions observed in clinical trials
① Adverse reactions that occurred when this drug (dutasteride 0.2 mg) was administered alone in clinical trials for male pattern hair loss
The safety of this drug (dutasteride 0.2mg) group, placebo group, and exploratory dutasteride 0.5mg group were evaluated and compared in 139 male androgenetic alopecia patients after 24 weeks compared to the baseline.
Of the total 139 test subjects, 50 adverse reactions were reported in 29 (20.86%) and 24 adverse drug reactions (ADRs) were reported in 16 (11.51%). Three serious adverse events (SAEs) were reported in 3 patients (2.16%) and were not related to this drug.
The adverse reactions judged to be related to this drug (dutasteride 0.2mg) were as follows.
[Table 1] Adverse drug reactions (* refer to manual)
② Adverse reactions that occurred when dutasteride 0.5mg was administered alone in clinical trials for male pattern hair loss
Dutasteride 0.5 mg was studied for the treatment of male pattern hair loss in two 6-month placebo-controlled phase 3 clinical trials and one phase 2 clinical trial. In these clinical trials, the adverse reactions that investigators judged to be related to dutasteride 0.5 mg (frequency greater than 2%) are as follows and were reported more frequently with dutasteride 0.5 mg compared to placebo.
[Table 2] Adverse reactions judged to be related to dutasteride 0.5mg (frequency of 2% or more) (* refer to manual)
2) Domestic post-marketing survey
The information specified below is based on what was collected during post-marketing surveillance for Dutasteride 0.5 mg.
① Results of a post-marketing use survey conducted on 712 adult males (18 to 41 years old) who received 0.5 mg of dutasteride for the treatment of male pattern hair loss over a period of 4 years (July 23, 2009 - July 22, 2013) for re-examination in Korea.
- The adverse event rate was reported to be 15.4% (110/712 people, 138 cases) regardless of causal relationship. Among these, the incidence of adverse drug reactions for which a causal relationship with 0.5 mg of dutasteride cannot be ruled out was 9.3% (66/712 people, 80 cases), with 9 cases of decreased libido, 8 cases of indigestion, 7 cases of erectile dysfunction, 5 cases each of fatigue and increased SGPT, and 4 cases each of rash and sexual dysfunction. The occurrence rate of serious adverse events was 0.6% (4/712 people, 5 cases) regardless of causal relationship. Two cases of pharyngitis, one case each of appendicitis, fracture, and viral infection were reported, but they did not correspond to serious adverse drug reactions. The incidence of unexpected adverse events was 8.1% (58/712 people, 69 cases) regardless of causal relationship: 6 cases of pharyngitis, 5 cases of increased SGPT, 4 cases each of acne and fungal dermatitis, 3 cases each of seborrhea, skin disease, and increased SGOT, 2 cases each of folliculitis, eczema, appendicitis, fatty liver, chest pain, palpitations, warts, contact dermatitis, Dry skin, peptic ulcer, gastritis, gastroenteritis, drowsiness, bilirubinemia, upper respiratory tract infection, fracture, unspecified abrasion, surgical intervention, laceration, hyperuricemia, hypertriglyceridemia, weight gain, paresthesia, decreased testosterone, skeletal pain, plantar fasciitis, viral infection, bacterial infection, purpura, epistaxis, blepharitis, benign laryngeal neoplasm, nephrolithiasis, dysgeusia, telangiectasia. It was reported in order of 1 case, of which the adverse drug reaction rate for which a causal relationship with 0.5 mg of dutasteride cannot be ruled out was 3.5% (25/712 people, 29 cases), with 5 cases of increased SGPT, 3 cases of increased SGOT, 2 cases each of acne, skin disease, folliculitis, palpitations, fungal dermatitis, seborrhea, warts, drowsiness, bilirubinemia, pharyngitis, surgical intervention, One case each of hypertriglyceridemia, weight gain, paresthesia, decreased testosterone, nosebleeds, and dysgeusia were reported in that order.
② As a result of integrated evaluation of the domestic reexamination adverse event and spontaneous side effect reporting data for Dutasteride 0.5mg with the adverse event reporting data reported for all domestically approved drugs at the end of reexamination, the newly confirmed adverse events that were statistically significantly more reported in Dutasteride 0.5mg compared to the adverse events reported in all other drugs are as follows. However, this result does not mean that a causal relationship has been proven between the ingredient and the following adverse events.
- Skin and appendage disorders: acne, dry skin
- Visual impairment: visual abnormality
- Liver and biliary tract diseases: fatty liver
- Metabolic and nutritional diseases: thirst
- Urinary system diseases: urinary abnormalities, hematuria
- Reproductive dysfunction (male): Semen abnormality
- Neoplasm: Gastric carcinoma
5. General precautions
1) Blood donation
To prevent the drug from being administered to a pregnant woman during a blood transfusion, patients taking this drug should not donate blood until at least 6 months have passed since the last time they took this drug.
2) Prostate-specific antigen (PSA)
① This drug reduces total serum PSA concentration. Therefore, in order to interpret the serum PSA value in men taking this drug, the initial value of PSA concentration must be reset 3 to 6 months after administration of this drug, and this new initial value should be used to evaluate potential changes in PSA value related to cancer.
② For patients taking this drug who need prostate cancer screening, a new PSA baseline value must be established 6 months after taking this drug. It is recommended to monitor PSA values regularly thereafter. A confirmed increase in PSA from the nadir level during treatment with this drug may be a sign of the presence of prostate cancer or refractoriness to treatment with this drug and should be carefully evaluated, even if such values are within the normal range for men not taking 5α-reductase inhibitors. In interpreting PSA values for patients taking this drug, previous PSA values should be referenced for comparison. Administration of this drug does not preclude the use of PSA as an adjunct to the diagnosis of prostate cancer after a new PSA baseline level has been established.
③ The total serum concentration of PSA will return to the initial value within 6 months after discontinuation of this drug.
④ The ratio of free PSA value to total PSA value remains constant while taking this drug. If a physician chooses the percentage of free PSA to diagnose prostate cancer in male patients taking this drug, no correction to this value is necessary.
3) Prostate cancer
In a clinical trial in which 0.5 mg of dutasteride or placebo was administered for 4 years to 8,231 men aged 50 to 75 years with a baseline PSA level of 2.5 ng/mL to 10.0 ng/mL and a previous negative biopsy for prostate cancer, 1,517 men were diagnosed with prostate cancer. The frequency of Gleason grade 8 to 10 prostate cancer was higher in the dutasteride 0.5 mg group (n=29, 1.0%) compared to the placebo group (n=19, 0.5%). There was no increase in the incidence of Gleason grade 5 to 6 or 7 to 10 prostate cancer. The causal relationship between dutasteride and high-grade prostate cancer has not been proven, and the clinical significance of the numerical imbalance is unknown. However, because dutasteride may increase the risk of developing high-grade prostate cancer, men taking this drug should be periodically evaluated for their risk of prostate cancer, including a PSA test. In a 2-year extended follow-up study of the clinical trial subjects, similar results were observed regarding the development of new prostate cancer (dutasteride 0.5mg [n=14, 1.2%], placebo [n=7, 0.7%]), among which there were no newly confirmed cases of Gleason grade 8 to 10 prostate cancer.
4) Breast cancer was reported in men who received 0.5 mg of dutasteride during clinical trials and post-marketing surveillance. In epidemiological studies, no increase in the risk of developing male breast cancer was observed following administration of 5α-reductase inhibitors. Physicians should instruct patients to promptly report any changes in breast tissue, such as lumps or nipple discharge. The causal relationship between long-term administration of dutasteride and the development of male breast cancer is not clear.
5) Effects on fertility
When dutasteride 0.5mg/day was administered to healthy subjects aged 18 to 52 years (dutasteride n=27, placebo n=23) for 52 weeks, the effect of dutasteride 0.5mg on semen characteristics was evaluated during the 52-week administration period and 24 weeks of follow-up period after the end of administration. At week 52, the average rate of decrease from initial values in total sperm count, semen volume, and sperm motility in the dutasteride 0.5 mg group was 23%, 26%, and 18%, respectively, when adjusted for the average decrease rate in the placebo group. Sperm concentration and sperm morphology were not affected. After a 24-week follow-up period, the average rate of change in total sperm count in the dutasteride 0.5 mg group was 23% lower than the initial value. At each test point, the average values of all semen-related evaluation variables were within the normal range, and there were no clinically significant changes (preliminarily defined as 30%). However, in two subjects in the dutasteride 0.5 mg treatment group, the sperm count at week 52 decreased by more than 90% from the initial value, and partially recovered at week 24 after the end of administration. The clinical significance of the effect of dutasteride on the characteristics of semen, which is the reproductive capacity of each patient, has not yet been revealed.
6) Information for patients
① Pregnant women or women with the potential to become pregnant should not handle this drug due to its absorption potential and potential risk to the developing male fetus due to absorption.
② Patients should be informed that the amount of ejaculation may decrease in some patients while taking this drug. Reduced ejaculate volume does not appear to interfere with normal sexual function. In clinical trials, erectile dysfunction and decreased sexual desire occurred in a small number of subjects administered this drug (dutasteride 0.2 mg), dutasteride 0.5 mg, or placebo, and the researchers judged it to be related to the test drug.
③ To prevent this drug from being administered to pregnant women during blood transfusion, patients taking this drug should not donate blood until at least 6 months have passed since the last time they took this drug.
7) Based on the pharmacodynamic and pharmacokinetic properties of this drug, this drug is not expected to affect the ability to drive or operate machinery.
8) Heart failure
In two 4-year clinical trials, the frequency of heart failure (adverse reactions mainly reported as heart failure and congestive heart failure) was found to be higher in patients receiving dutasteride 0.5 mg in combination with an α-blocker (mainly tamsulosin) than in patients not receiving the combination. The incidence of heart failure in these two trials was low (≤1%) and differed between the two trials. No imbalance in the overall frequency of cardiovascular adverse events was observed in either trial. A causal relationship between dutasteride (either alone or in combination with α-blockers) and heart failure has not been established.
6. Interaction
1) In in vitro drug metabolism studies, dutasteride was metabolized by human CYP3A4, so the blood concentration of this drug may increase in patients taking CYP3A4 inhibitors. Therefore, caution should be exercised when administering this drug to patients chronically taking strong CYP3A4 inhibitors.
2) When administered at 0.5 mg of dutasteride, it did not inhibit the in vitro metabolism of substrates of major human CYP450 isoenzymes (CYP1A2, CYP2A6, CYP2E1, CYP2C8, CYP2C9, CYP2C19, CYP2B6, and CYP2D6) at a concentration of 1000 ng/mL, which is 25 times higher than the human steady-state serum concentration. Additionally, dutasteride did not induce CYP P450 isoenzymes CYP1A, CYP2B, or CYP3A in in vivo tests in dogs and rats.
3) Calcium channel antagonist: Dutasteride 0.5mg As a result of pharmacodynamic (PK) analysis of phase 2 clinical trial data, a decrease in clearance of dutasteride was confirmed when the CYP3A4 inhibitor verapamil (-37%, n = 6) and diltiazem (-44%, n = 5) were co-administered. Conversely, when dutasteride 0.5 mg was co-administered with amlodipine (+7%, n = 4), a calcium channel antagonist rather than a CYP3A4 inhibitor, no decrease in the clearance of dutasteride was observed.
When co-administered with CYP3A4 inhibitors (e.g. verapamil and diltiazem), the decreased clearance of dutasteride and the resulting increased exposure are not considered clinically significant due to the wide safety margin of dutasteride (up to 10 times the dose of 0.5 mg of dutasteride has been administered to patients for up to 6 months), so dose adjustment is not recommended.
4) α-Adrenergic blockers: In a cross-over study on healthy volunteers, when 0.5 mg of dutasteride was co-administered with tamsulosin or terazosin for 2 weeks, it did not affect the steady-state pharmacokinetics or pharmacodynamics of these α-adrenergic blockers. The rate of change in 5α-dihydrotestosterone (DHT) concentration during combined administration was similar to that when dutasteride 0.5 mg was administered alone.
In clinical trials, 0.5 mg of dutasteride and tamsulosin were administered in combination for 24 weeks, and then 0.5 mg of dutasteride and tamsulosin were administered together for 12 weeks, or 0.5 mg of dutasteride was administered alone. After a 12-week administration period, compared to the dutasteride 0.5mg single administration group, there were no excessively severe adverse reactions in the combination administration group or discontinuation of the test drug due to adverse reactions.
5) In in vitro tests, dutasteride replaces warfarin, diazepam, acenocoumarol, phenprocoumon, or phenytoin at the plasma protein binding site, or these model compounds do not replace dutasteride.
6) Warfarin: When dutasteride 0.5 mg/day was co-administered with warfarin to 23 healthy subjects for 3 weeks, it did not change the steady-state pharmacokinetics of S- or R-warfarin isomers, nor did it change the effect of warfarin on prothrombin time.
7) Digoxin: When dutasteride 0.5 mg/day was co-administered with digoxin to 20 healthy subjects for 3 weeks, it did not change the steady-state pharmacokinetics of digoxin.
8) Cholestyramine: When 12 g of cholestyramine was administered to 12 normal volunteers one hour after a single dose of 5 mg of dutasteride, it did not affect the relative bioavailability of dutasteride.
9) Other combination therapy: Although interaction tests with other drugs were not specifically conducted, approximately 90% of subjects who received 0.5 mg of dutasteride in phase 3 clinical trials were taking other drugs concurrently. In clinical trials, when 0.5 mg of dutasteride was co-administered with antihyperlipidemic agents, angiotensin-converting enzyme (ACE) inhibitors, β-adrenergic blockers, calcium channel blockers, corticosteroids, diuretics, non-steroidal anti-inflammatory drugs (NSAIDs), phospho-diesterase Type V (PDE5) inhibitors, and quinolone antibiotics, co-administration with dutasteride was effective. There were no clinically significant negative interactions attributable to this study.
7. Administration to pregnant and lactating women
1) Administration to pregnant women
This drug is contraindicated in women. This drug was not tested in women because nonclinical study results suggested that external genital development may be impaired in male fetuses conceived by exposed women due to inhibition of circulating dihydrotestosterone (DHT) levels.
2) Administration to nursing mothers
This drug is contraindicated in women. It is not known whether this drug passes into human breast milk.
8. Administration to children
This drug is contraindicated in children under 18 years of age. Safety and efficacy in children under 18 years of age have not been established.
9. Administration to elderly people
Clinical trials for the treatment of male pattern hair loss were conducted on adult male patients under the age of 50. There are no efficacy data for patients with male pattern hair loss over 50 years of age.
10. Effect on clinical test values
1) PSA level
As a result of observing PSA values at 12 and 24 weeks in subjects who received this drug (dutasteride 0.2 mg) during clinical trials, there was a statistically significant decrease compared to the baseline.
During clinical trials, the PSA value decreased by 20% within one month of administration in approximately half of the subjects who received 0.5 mg of dutasteride. Six months after administration, the PSA value stabilized to a new initial value of approximately 50% of the value before administration. Even after administering 0.5 mg of dutasteride for up to 2 years, the PSA value continued to decrease by up to 50%.
The initial PSA value must be reset 3 to 6 months after administering this drug.
2) Hormone levels
Testosterone and dihydrotestosterone levels were observed at 12 and 24 weeks in subjects who received this drug (dutasteride 0.2 mg) during the clinical trial. As a result, testosterone increased statistically significantly and dihydrotestosterone decreased compared to the baseline.
In healthy adults, no clinically significant changes were observed in the levels of globulin-binding sex hormones, estradiol, luteinizing hormone, follicle-stimulating hormone, thyroxine (free T4), and dehydroepiandrosterone when dutasteride 0.5 mg (n = 26) was administered for 52 weeks compared to placebo (n = 23). Total testosterone (97.1ng/dL, p<0.003) at 8 weeks and thyroid-stimulating hormone (TSH) (0.4mcIU/mL, p<0.05) at 52 weeks were statistically significantly increased compared to the placebo group. Within the dutasteride 0.5 mg administration group, the median change from baseline was 17.9% at 8 weeks for testosterone and 12.4% at 52 weeks for TSH. During the 24-week follow-up period after discontinuation of dutasteride, the average values of testosterone and TSH in subjects with analyzable samples recovered to baseline levels.
11. Treatment in case of overdose
There is no specific antidote for this drug, so when symptoms of overdose are suspected, appropriate supportive therapy should be administered considering the long half-life of this drug.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Removing medicines from their original container and storing them in another container may cause accidents due to misuse of medicines or cause a decrease in the quality of medicines, so keep them in their original containers.
13. Information for experts
1) Pharmacological action
Dutasteride is a 5α-reductase inhibitor that inhibits the conversion of testosterone to dihydrotestosterone (DHT).
2) Pharmacokinetic information
One randomized, open-label, single-dose, cross-over design, phase 1 clinical trial was conducted to compare and evaluate the pharmacokinetics and safety of this drug (dutasteride 0.2 mg) and Avodart soft capsule 0.5 mg (dutasteride 0.5 mg).
As a result of measuring dutasteride in the blood of 23 healthy adult men, the point estimate (90% CI) of the geometric mean ratio of log-transformed AUCt/dose and Cmax/dose between administration groups (0.5 mg of this drug/Avodart soft capsule) was 0.3150 (0.2740-0.3621), respectively. It was observed as 0.7441 (0.6527-0.8483).
3) Clinical trial information
One multicenter, randomized, double-blind, placebo-controlled, parallel phase 3 clinical trial was conducted to compare and evaluate the safety and efficacy of this drug (dutasteride 0.2mg, test group), placebo (placebo group), and dutasteride 0.5mg (exploration group) in 137 male patients with androgenetic alopecia once daily for 24 weeks.
The subjects of the clinical trial were men aged 18 or older and 50 or younger who were diagnosed with androgenetic alopecia corresponding to M2 or C2 or higher, V1 or F1 or higher (excluding M2 or M3 alone) according to the BASP classification. The most frequent age group was 40-50 years old (approximately 60% of the total), and among the BASP classifications, M2-3/V1-3 was included at approximately 60%, M2-3/F1-3 at approximately 25%, and other classifications accounted for less than 10% each.
As a primary efficacy endpoint, the change in the total number of hairs in a unit area circle (㎠) at 24 weeks compared to the baseline was evaluated, and a statistically significant increase was observed in the test group compared to the placebo group, showing superiority over placebo (p value = 0.0072).
[Table 3] Change in total number of hairs in unit area circle (㎠) at 24 weeks compared to baseline (* refer to manual)
4) Toxicity test information
(1) Central nervous system toxicity
When dutasteride was repeatedly administered orally to rats and dogs, non-specific, reversible, and central nervous system-mediated toxicity was observed in some experimental animals. However, no relevant histopathological changes were observed when dutasteride was administered at 425 and 315 times the expected clinical exposure, respectively, at 0.5 mg per day.
(2) Carcinogenicity
In a 2-year carcinogenicity study in B6C3F1 mice, males were administered doses of 3, 35, 250, and 500 mg/kg/day, and females were administered doses of 3, 35, and 250 mg/kg/day. An increase in the incidence of benign hepatocellular adenoma was confirmed only in females administered 250 mg/kg/day (290 times the expected clinical exposure when administering 0.5 mg of dutasteride per day). Two of the three major metabolites in humans were identified in mice. It is not known whether exposure to these metabolites in mice is lower than in humans.
In a 2-year carcinogenicity study on Han Wistar rats, doses of 1.5, 7.5, and 53 mg/kg/day were administered to males, and doses of 0.8, 6.3, and 15 mg/kg/day to females. Leydig cell adenomas increased in the testes of males administered 53 mg/kg/day (135 times the expected clinical exposure when administered 0.5 mg of dutasteride per day), and Leydig cells increased in the testes of males administered 7.5 mg/kg/day (52 times the expected clinical exposure when administered 0.5 mg of dutasteride per day) and 53 mg/kg/day. An increased incidence of hyperplasia was observed. A positive correlation between the proliferation changes of Leydig cells and the increase in circulating luteinizing hormone levels was demonstrated by 5α-reductase administration, which was consistent with the effect on the hypothalamic-pituitary-testicular axis after 5α-reductase inhibition. At the carcinogenic dose in rats, rat luteinizing hormone levels increased by 167%. In this study, the carcinogenicity of dutasteride's major metabolites in humans was tested when exposed to approximately 1 to 3 times the expected clinical exposure when administered at 0.5 mg per day. In carcinogenicity tests on rats, benign stromal cell tumors increased when administered at high doses (158 times the expected clinical exposure when dutasteride was administered at 0.5 mg per day). However, the endocrine mechanisms thought to be involved in mesangial cell hypertrophy and adenomas in rats are not relevant to humans. Carcinogenicity studies in mice showed no clinically relevant effects on tumor profile.
(3) Hereditary
Dutasteride did not show genotoxicity in various in vitro and in vivo tests.
The results of the bacterial mutagenicity test (Ames test), chromosomal aberration test in CHO cells, and micronucleus test in rats did not indicate the possibility of dutasteride being genotoxic. The two major metabolites in humans were also not mutagenic in the Ames test or modified Ames test.
(4) Reproductive and developmental toxicity
When dutasteride 0.05, 10, 50, and 500 mg/kg/day (0.1 to 110 times the expected clinical exposure when administering 0.5 mg of dutasteride per day) was administered to sexually mature male rats for up to 31 weeks, reproductive performance decreased in a dose- and time-dependent manner, and the number of sperm in the epididymis decreased, but sperm concentration did not decrease (50, 500mg/kg/day), the weight of the epididymis, prostate, and seminal vesicles decreased, and microscopic changes appeared in the male reproductive organs. In all test drug administration groups, reproductive function recovered at 6 weeks of recovery, and sperm count became normal at the end of 14 weeks of recovery. 5α-reductase-related changes included cytoplasmic vacuolization of epididymal tubular epithelial cells and decreased cytoplasmic content of epithelial cells, consistent with decreased secretory activity in the prostate and seminal vesicles. In the low-dose group, microscopic changes no longer appeared at 14 weeks of recovery, and there was partial recovery in the remaining dose groups. When males administered 10, 50, or 500 mg/kg/day for 29 to 30 weeks were mated with females not administered the test drug, low concentrations (0.6 to 17 ng/mL) of dutasteride were detected in the serum of the females. Dutasteride caused a reversible decrease in fertility in male rats, which is consistent with its pharmacological activity in 5α-reductase inhibition on accessory reproductive organs. This effect is not considered clinically significant because there was no effect on sperm development, concentration, or motility.
In an embryo-fetal development study in female rats, oral administration of dutasteride 0.05, 2.5, 12.5, and 30 mg/kg/day resulted in feminization of male fetuses (reduced anogenital distance) and male neonates (nipple development, hypospadias, and preputial gland swelling) at all doses. In relation to weight loss, an increased incidence of skeletal muscle deformation related to delayed ossification was observed at doses of 12.5 and 30 mg/kg/day (56 to 111 times the expected clinical exposure when administering 0.5 mg of dutasteride per day). In addition, at doses above 2.5 mg/kg/day (2 to 10 times the expected clinical exposure when administering 0.5 mg of dutasteride per day), the number of litters decreased, and embryo resorption and feminization of male fetuses increased. Fetal weight also decreased at doses above 0.05 mg/kg/day (less than 0.02 times the expected clinical exposure when administering 0.5 mg of dutasteride per day).
In a perinatal orally administered test to rats, dutasteride was administered at doses of 0.05, 2.5, 12.5, and 30 mg/kg/day. Feminization of the genitalia of F1 generation male neonates (e.g., decreased anogenital distance, increased hypospadias, and nipple development) was evident at doses above 2.5 mg/kg/day (14 to 90 times the estimated clinical exposure for dutasteride at 0.5 mg/day). At a dose of 0.05 mg/kg/day (0.05 times the expected clinical exposure when administering 0.5 mg of dutasteride per day), there was a small but statistically significant decrease in anogenital distance as evidence of feminization. When 2.5 to 30 mg/kg/day was administered, the gestation period in female mothers increased, the time to vaginal opening in female newborns, and the seminal vesicle weight in male newborns decreased. The effect on neonatal stimulation response was observed at doses higher than 12.5 mg/kg/day. At the dose of 30mg/kg/day, the number of stillbirths increased.
Feminization of male fetuses is an expected physiological result of inhibition of conversion of testosterone to DHT by administration of 5α-reductase inhibitors. These results are similar to those observed in male newborns genetically deficient in 5α-reductase.
In a rabbit embryo-fetal test, 30, 100, and 200 mg/kg (28 to 93 times the expected clinical exposure when dutasteride is administered at 0.5 mg per day) was administered on days 7 to 29 of conception, which corresponds to the final period of external genitalia development. When the papillary papillae of the fetuses were evaluated histologically, evidence for feminization of male fetuses was found at all doses. A second embryo-fetal study in rabbits administered doses of 0.05, 0.4, 3.0, and 30 mg/kg/day (0.3 to 53 times the estimated clinical exposure for dutasteride administered at 0.5 mg/day) also showed evidence of genital feminization in male fetuses at all doses. It is not known whether major human metabolites are present in rabbits or rhesus monkeys. However, when dutasteride was administered intravenously during the embryo-fetal development period of pregnant monkeys at doses up to 2010 ng/animal/day, no harmful maternal or fetal toxicity was observed. In an embryo-fetal development test (12/group) in rhesus monkeys, dutasteride 400, 780, 1325, and 2010 ng/day administered intravenously on days 20 to 100 of conception did not cause any adverse reactions in the development of male external genitalia. In monkeys administered the highest dose, a decrease in the weight of the fetal adrenal gland, a decrease in the weight of the fetal prostate, and an increase in the weight of the fetus's ovaries and testes were observed. The maximum concentration of dutasteride detected in the semen of a man who received repeated oral administration of 0.5 mg of dutasteride for 12 months was 14 ng/mL. Assuming that dutasteride is 100% absorbed by a 50 kg woman through 5 mL of semen per day, the maximum amount of dutasteride that can be exposed is 1.4 ng/kg. In an embryo-fetal development test administered intravenously to rhesus monkeys, there was no effect on male fetal development even at a concentration of 260ng/kg (corresponding to 186 times the maximum exposure to women through human semen when dutasteride is administered at 0.5mg per day) when converted to ng/kg. Because dutasteride has a very high binding rate (> 96%) to proteins in human semen, vaginal absorption is likely to be reduced.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/box (10 tablets/PTPX3)
7. Period of use
36 months from date of manufacture